低剂量口服依托泊苷治疗晚期非小细胞肺癌

Oral low-dose etoposide for advanced non-small-cell lung cancer

目的 :评价依托泊苷低剂量持续口服治疗晚期非小细胞肺癌的临床效果。方法 :对 2 2例晚期非小细胞肺癌病人采用依托泊苷软胶囊口服 ,剂量按 5 0mg·m- 2 ·d- 1计算 ,实际剂量 (46±s3)mg·m- 2 ·d- 1,晨起空腹一次顿服 ,连服 2 1d ,每 2 8～ 35d为一个周期。按WHO实体瘤疗效评价标准及毒副作用标准确定疗效及毒副作用。结果 :病人接受(2 .9± 0 .9)个周期化疗后 ,部分缓解占 2 3% (5 /2 2 ) ,稳定占 36 % (8/ 2 2 ) ,进展为 4 1% (9/ 2 2 )。毒副作用轻微。结论 :依托泊苷软胶囊低剂量持续口服对晚期非小细胞肺癌病人获得较好的疗效 ,毒副作用轻微 。

AIM: To investigate the clinical effect of oral low dose etoposide in treating advanced non small cell lung carcinoma (NSCLC). METHODS: Twenty two patients with NSCLC were treated with oral etoposide (46± s 3) mg·m -2 ·d -1 (41-52 mg·m -2 ·d -1 ), qm, ac×21d, Every 28-35 d was a peried. Effective evaluation was performed using WHO standard criteria. Toxicities were reported using the WHO grading sytem. RESULTS: The patients received (2.9±0.9) chemotherapy periods. The partial response was 23% (5/22). The stable was 36%(8/22). The Progressive was 41% (9/22). The 95% confidence interval of effective rate was from 8% to 45%. The toxicity was slight. CONCLUSION: The continuous oral low dose etoposide in advanced stage NSCLC has a better effect and a slight toxicity.